Committed to the fight against cancer and CNS disorders

Committed to the fight against cancer and CNS disorders

Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI^® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML

Astex has built a rich product portfolio with multiple drugs in clinical development

Latest from Astex

7 July 2020

Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML

11 February 2020

Astex Pharmaceuticals announces U.S. Food and Drug Administration (FDA) acceptance for review of an NDA for the combination oral hypomethylating agent cedazuridine and decitabine (ASTX727 or oral C-DEC), for the treatment of MDS and CMML

In The News

14 May 2020
Astex CSO, David Rees, elected as new Fellow of the Academy of Medical Sciences

Sustaining innovation

Innovative postdoctoral research fellowships

Career Opportunities

We seek to attract and retain talented individuals who are passionate about improving patient outcomes.